Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MINIZIDE is a fixed-dose combination oral capsule containing polythiazide (a thiazide diuretic) and prazosin hydrochloride (an alpha-1 adrenergic antagonist) approved in 1980 for hypertension management. The combination leverages complementary mechanisms: prazosin provides vasodilation and alpha-blockade while polythiazide enhances sodium and water excretion, creating synergistic blood pressure reduction. This adjunctive therapy was designed for patients requiring dual antihypertensive action.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a defensive commercial posture focused on retention rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MINIZIDE offers limited career growth given its LOE-approaching lifecycle and zero linked job openings; opportunity is primarily in defensive brand management and transition planning. This assignment is best suited for early-career professionals seeking stable, lower-pressure experience or specialists in product lifecycle management and generic transition strategy.
Worked on MINIZIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.